Free Newsletter
Red tide research points to cystic fibrosis therapy
Scientists at MIT have synthesized red tide toxin in what could be a significant advance toward developing new therapies to treat cystic fibrosis. Their goal was to determine the chemical machinery at work in developing the toxins which create red tide. Synthesizing brevetoxin and related compounds pointed to a potential new approach in cystic fibrosis. Brevenal acts as an antagonist to brevetoxin.
"It's very potent in what's called 'mucus movement,'" said MIT's Timothy Jamison. "That's the golden term in cystic fibrosis, from what I understand."
- read the report from The News-Press
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




